Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pathologic Complete Response × Radiation × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 73 Prostatic Neoplasms 53 Breast Neoplasms 50 Carcinoma, Non-Small-Cell Lung 46 Esophageal Neoplasms 43 Lung Neoplasms 37 Rectal Neoplasms 36 Head and Neck Neoplasms 31 Gliosarcoma 30 Brain Neoplasms 30 Squamous Cell Carcinoma of Head and Neck 29 Uterine Cervical Neoplasms 27 Pancreatic Neoplasms 26 Neoplasms 22 Neoplasm Metastasis 21 Sarcoma 20 Glioma 19 Melanoma 18 Esophageal Squamous Cell Carcinoma 18 Oropharyngeal Neoplasms 17 Astrocytoma 16 Adenocarcinoma Of Esophagus 14 Stomach Neoplasms 12 Carcinoma, Squamous Cell 12 Urinary Bladder Neoplasms 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Lymphoma, Follicular 10 Central Nervous System Neoplasms 10 Mouth Neoplasms 9 Endometrial Neoplasms 9

Interventions

Trastuzumab 6 Carboplatin 6 Docetaxel 5 Paclitaxel 4 Oxaliplatin 4 Fluorouracil 4 Cytarabine 4 Cyclophosphamide 4 Azacitidine 4 pertuzumab 3 pembrolizumab 3 Radiotherapy 3 Observation 3 Epirubicin 3 Endoscopy 3 Cisplatin 3 Chemoradiotherapy 3 Capecitabine 3 venetoclax 2 sargramostim 2 olaparib 2 durvalumab 2 cc-486 2 Surgical Procedures, Operative 2 Standard of Care 2 Pemetrexed 2 Neoadjuvant Therapy 2 Monatide (IMS 3015) 2 Metformin 2 Magnetic Resonance Imaging 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07472868 2026-03-16

MEND-IT II

Catharina Ziekenhuis Eindhoven

Phase 3 Not yet recruiting

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon ⚡